Objectives: To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multi-parametric MRI (mpMRI) studies are classifiable by ProstateSpecific Antigen (PSA), PSA density (PSAD), PI-RADS_v2 rescoring and morphological MRI features.
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INTRODUCTION:
Multi-parametric MRI (mpMRI) has the potential to be the modality of choice for ruling out clinically significant prostate cancer with reported negative predictive values as high as 89% (83-94%) (1, 2) . However, prostate mpMRI is scored as indeterminate (Likert-score 3/5) in almost 1/3 rd of cases (163 of 576 patients enrolled in the recent multi-centre prospective PROMIS study)
where the radiologist is unable to confirm or refute the presence of clinically significant cancer.
Two scoring systems are commonly used to evaluate the likelihood of prostate cancer on mpMRI (3) (4) (5) (6) . First, the Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) which uses explicit criteria based on a zonal mpMRI dominant sequence (e.g diffusion-weighted imaging in the peripheral zone and T2-weighted imaging in the transition zone) to rate the suspicion of prostate cancer on a five-point scale (7) and second, a subjective five-point Likert assessment (8) , based on each mpMRI sequence equally (unlike the use of dominant sequence in PIRADS_v2) and adapted to the radiologist's experience for overall impression. Both 5-point scales define the likelihood for the presence of prostate cancer, as follows 1: highly unlikely, 2:
unlikely, 3: equivocal, 4: likely, 5: highly likely). Subjective Likert scoring has recently been prospectively validated in the multi-centre, multi-reader PROMIS trial (1) . PI-RADS_v2 remains more widely accepted where prospectively scored cohorts have also been reported (9) but studies with head-to-head comparisons of PI-RADS_v2 and Likert-assessment as scoring systems are lacking.
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Indeterminate mpMRI poses both a management dilemma and potential unnecessary increase in healthcare cost. If all patients within this group were biopsied, a majority of men without significant disease would be exposed to potentially unnecessary risks of haemorrhage and urinary tract infections, which can lead to hospitalization (10) further increasing healthcare costs;
conversely, if all men were not biopsied then a significant proportion of men would have significant cancer missed. This cohort of patients has been scarcely studied as an independent group (11, 12) since most attention so far, has been focused on both extremes of the scale (13) (14) (15) (16) . Decreasing the number of equivocal mpMRI scans remains an unmet clinical challenge and represents a determinant factor for widespread global adoption of mpMRI.
The prevalence of prostate cancer is higher in the peripheral zone than the transition zone and zone-specific molecular and imaging phenotypes exist, prompting separate zonal assessment (17) (18) (19) .
The aim of this work was to determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multi-parametric MRI (mpMRI) studies can be categorized into significant/insignificant cancer by Prostate-Specific Antigen (PSA), PSA density (PSAD), PI-RADS_v2 rescoring and morphological MRI features. (21) . In addition, when a focal lesion was identified on mpMRI, its location was mapped on a prostate gland representative diagram and its biopsy template grid co-ordinates noted (21) .
MATERIALS AND METHODS
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MR-guided targeted biopsies were performed by experienced urologists (≥ 10 years of experience), aware of the radiologist's report, as described within the previous study protocol (20) .
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patients fulfilled these criteria. Patients with a concurrent Likert-score 3/5 in the transition zone (TZ) subsequently identified as clinically significant tumour were excluded (n=6), men with a lack of complete gland sampling/ inadequate sampling density were excluded (n=20), and five men who underwent 1.5T
scans were excluded. The final cohort comprised of 76/107 PZ Likert-scored 3/5 mpMRI studies for analysis. Figure 1 summarizes the patient selection.
MpMRI Protocol
The 3T mpMRI protocol for included men (Table 1) has been previously described (22) . All studies were performed with the same protocol on a single 3T scanner (Achieva ® , Philips Healthcare, Netherlands) using a 32-channel pelvic-phased array coil. Briefly, sequences included axial turbo spin echo and coronal T2W; axial DWI using a high b-value at 2000s/mm 2 ; axial ADC map generated by diffusion gradients b0, b150, b500, and b1000 (s/mm 2 ) and axial T1W dynamic-contrast enhanced sequences before and after intravenous administration of at least 0.1 mmol/kg gadolinium meglumine contrast agent (Dotarem ® , Guerbet, France) at a rate of 3ml/s via power injector, followed by 20ml saline bolus at the same rate with a temporal resolution of 15 seconds. 
Cancer Significance
PZ was considered as clinically significant (23) . The maximum cancer core length (MCCL) was measured and categorized as <6mm or ≥6mm.
Correlation of Trans-perineal Template Mapping Biopsies and MpMRI
For mpMRI to histopathology matching, Likert-scores 3/5 at the apex and base were considered positive for significant cancer if the corresponding Serum PSA and PSA Density PSA prior to entry of patients into the previous study (14) was recorded. To calculate PSA density, the prostate volume was measured on the mpMRI study. The maximum antero-posterior and latero-lateral diameters of the prostate were manually measured by Reader A on axial T2W slices while its cranio-caudal diameter was measured on coronal T2W slices as shown in Figure 3 . Assuming an ellipsoid shape of the prostate, its volume was calculated by Reader A as the product of the three diameters and π/6 (24).
PSAD was calculated by the quotient of serum PSA over the gland volume.
Likert to PI-RADS Scoring
Reader A, who reported the mpMRI of the prostate as Likert-score 3/5 in the previous study (22) , rescored them with PI-RADS_v2 criteria (8) . A second radiologist, Reader B (4 years of experience in reading prostate mpMRI) 
independently rescored the scans, using first Likert scoring, then at different time points with PI-RADS_v2. Both readers were blinded to histopathological reports, unaware of each other's scores.
Peripheral Zone MpMRI Morphology
As Likert-score 3/5 exhibit varied appearances on mpMRI, the presence/absence of the morphological descriptors (described below and in ii) "diffuse homogeneous" -uninterrupted signal changes occupying >50% of PZ, and without focal intensity variation, iii) "diffuse inhomogeneous" -signal changes occupying >50% of PZ interrupted by focal intensity variation or stranded changes
Statistical Analyses
The Mann-Whitney tests were used to compare each PSA and PSAD between clinically significant and non-significant/no cancer groups. From a receiver-operating characteristic (ROC) curve, sensitivity and specificity of various PSAD thresholds were obtained and the highest Youden's J index 
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10 was determined to identify PSAD threshold for significant cancer in our cohort (25 GraphPad Software, San Diego, CA) was used.
RESULTS
Of 76 men (median age 61 years IQR 57-66; median PSA 7.2 ng/ml IQR 4.9-10.3; median gland volume 52 cc IQR 33-63), 21 (27%) had a clinically significant cancer at biopsy, 31 (41%) harbored low grade (Gleason 3+3) disease, and 24 (32%) had no cancer (including high-grade prostate intraepithelial neoplasm, atypical acini, inflammation, atrophy, and/or benign cores).
Serum PSA and PSA Density
Median PSA and PSAD were 7.17 ng/ml (IQR: 5.55-8.69) and 0.19 ng/ml 2 (IQR: 0.13-0.29) in the significant cancer group while in the non-significant/no cancer group, these were 7.20 ng/ml (IQR: 4.31-10.7) and 0.13 ng/ml 2 (IQR:
0.10-0.17) respectively. PSAD was significantly higher in the significant cancer group (p=0.004) as represented in Figure 5 ; PSA was not significantly 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 
Likert to PI-RADS Rescoring
Of 76 patients, five had extensive post-biopsy artefact, leaving 71 patients eligible for PZ PI-RADS scoring. Among them, four had non-diagnostic quality DWI, due to air in the rectum, and PI-RADS 'Assessment without adequate DWI' was applied (8). 
Peripheral Zone mp-MRI Morphology
Sixty-seven men were included in this analysis after excluding non-diagnostic DWI studies. Results of qualitative mpMRI assessment are summarized in 
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14 prostatectomy with a 66% NPV (21 Muller et al (39) showed an overall =0.47 for PI-RADS_v2 scoring with mixed reader experience. Within our study, we found a smaller  of 0.27 for PIRADS_v2. We do not believe this to be surprising as we specifically assessed a subgroup (Likert 3/5) of patients where radiological assessment is inherently more challenging.
Finally, we investigated whether any particular pattern of PZ signal change could help classify patients. We found the group of patients with 'diffuse inhomogeneous' pattern did not include any patient with significant cancer.
However, the number of patients within our cohort was too small to confirm the statistical significance of this observation.
The results of our study are relevant to directing clinical practice following the recent PROMIS study publication with Likert-scored mpMRI (1). When 3/5-scores are classified as positive, the specificity of the mpMRI study is reduced (5, 40) . If these scores are classified as negative, the sensitivity of the mpMRI 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 Our study has several limitations. Firstly, it was necessary to use a template biopsy based reference in our cohort as it comprised many patients without significant cancer/any cancer and therefore could not have a prostatectomy.
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CONCLUSIONS
